Cargando…

17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.

BACKGROUND: Cannabidiol is a component of herbal cannabis, studied for a number of potential pharmaceutical indications, more recently, its potential anti-psychotic effects with an extremely favorable side effect profile. Cannabidiol content of cannabis may also attenuate the psychotic and cognitive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ranganathan, Mohini, D’Souza, Deepak, Cortes-Briones, Jose, Skosnik, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887318/ http://dx.doi.org/10.1093/schbul/sby014.066

Ejemplares similares

17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS
por: Bhattacharyya, Sagnik
Publicado: (2018)

T172. MULTIMODAL QUANTIFICATION OF MEMORY CIRCUIT MICROSTRUCTURE IN FIRST EPISODE PSYCHOSIS
por: Makowski, Carolina, et al.
Publicado: (2018)

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

Cannabidiol modulation of hippocampal glutamate in early psychosis
por: O’Neill, Aisling, et al.
Publicado: (2021)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD)
por: Crippa, Jose Alexandre, et al.
Publicado: (2018)

17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA
por: McGuire, Philip, et al.
Publicado: (2018)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion
por: Boggs, Douglas Lee, et al.
Publicado: (2016)

S172. BRAIN METABOLITES AND THE RELATION WITH COGNITION AND PSYCHOTIC SYMPTOMS IN MEDICATION-FREE PSYCHOSIS AND CONTROLS: A PHARMACOLOGICAL MAGNETIC RESONANCE SPECTROSCOPY STUDY
por: Vingerhoets, Claudia, et al.
Publicado: (2018)

S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2018)

Cannabidiol (CBD) and Insomnia : Literature review
por: Gutierrez Higueras, T., et al.
Publicado: (2022)

Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial
por: Dixon, T., et al.
Publicado: (2023)

Pharmacological treatment of early psychosis: risks and benefits
por: Sīle, L.
Publicado: (2023)

S17.2 Pan-resistant bugs (A. baumanii and P. aeruginosa): Antimicrobial therapy and infection control
Publicado: (2005)

172. Antimicrobial Stewardship in High-risk Pediatric Patients
por: Goldman, Jennifer, et al.
Publicado: (2018)

Early Intervention Programmes in Psychosis
por: Nordentoft, M.
Publicado: (2022)

172. Evaluation of Multifaceted Antimicrobial Stewardship Interventions on The Treatment of Asymptomatic Bacteriuria
por: Pham, Tho H, et al.
Publicado: (2020)

4.1 ENHANCING EARLY PSYCHOSIS TREATMENT USING SMARTPHONE TECHNOLOGY: INTEGRATION OF A MOBILE HEALTH PLATFORM IN FOUR EARLY PSYCHOSIS PROGRAMS
por: Tully, Laura, et al.
Publicado: (2018)

S172. GLUTAMATE RELATED CONNECTIVITY DISTURBANCES OF THE SALIENCE AND DEFAULT MODE NETWORKS IN PSYCHOSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

13.2 CANNABIDIOL AS AN ANTIPSYCHOTIC DRUG
por: Guimaraes, Francisco, et al.
Publicado: (2018)

CANNABIDIOL- PROVOKES OR TREATS ANXIETY DISORDERS?
por: Arshad, H., et al.
Publicado: (2023)

Parasuicidal behavior in early stages of psychosis
por: Serván Rendón-Luna, B., et al.
Publicado: (2023)

809. Osteitis Caused by Bacillus Calmette-Guerin Tokyo 172 Strain in Immunocompetent Patients
por: González Saldaña, Napoleón, et al.
Publicado: (2018)

Clinical high-risk criteria of psychosis in 8- to 17-year-old community subjects and inpatients not suspected to develop psychosis: not pluripotential or transdiagnostic
por: Schultze-Lutter, F., et al.
Publicado: (2022)

T33. EARLY INTERVENTION FOR EARLY PSYCHOSIS IN FRANCE, MAPPING OF PROGRAMS
por: Meunier-Cussac, Sophie, et al.
Publicado: (2018)

PS172. Cognitive function and white matter hyperintensity in elderly patients with depression
por: Lee, Miji, et al.
Publicado: (2016)

Disentangling early and late onset of psychosis in women
por: Díaz-Pons, A., et al.
Publicado: (2022)

Identifying early signs of Treatment Resistance in First Episode Psychosis to revise and aid further treatment
por: Wold, K. F., et al.
Publicado: (2023)

Sex differences in antipsychotic efficacy and side effects in psychosis
por: Erzin, G.
Publicado: (2023)

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

172 Can Procalcitonin (PCT) Be Used as an Early Marker of Sepsis in Patients with Intracranial Hemorrhage (ICH)?
por: Gautam-Goyal, Pranisha, et al.
Publicado: (2014)

Mental Disorders Forecast Alzheimer’s Disease and Related Dementias in 1.7 Million New Zealanders
por: Richmond-Rakerd, Leah, et al.
Publicado: (2021)

Vascular psychosis in the elderly. case report and literature review for different antypsichotic treatment strategies
por: Higueras, T. Gutiérrez, et al.
Publicado: (2021)

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2019)

Gone to Pot – A Review of the Association between Cannabis and Psychosis
por: Radhakrishnan, Rajiv, et al.
Publicado: (2014)

Increased risk of psychosis to ivermectin treatment
por: Romero Calderon, A., et al.
Publicado: (2022)

Innovations in treatment of psychosis in southeast europe
por: Jovanovic, N.
Publicado: (2023)

Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs
por: Garcia, Gabriel A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aruk3ke227dhs3f271qomeesqt